ArticleThe Journal of allergy and clinical immunology2018

Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.

Alexander Vargas-Hernández et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.